Allergan IP Deal With Tribe Could Have Big Impact On PTAB
Allergan PLC's attempt to use a Native American tribe's sovereign immunity to shield patents for its best-selling eye drug from inter partes review raises new questions for the Patent Trial and...To view the full article, register now.
Already a subscriber? Click here to view full article